Abstract: The present invention provides antigen presenting cells (APC) carrying human tumor-associated peptides on the cell surface as well as immunogenic compositions including the tumor-associated peptides and/or the antigen presenting cells according to the invention. The immunogenic composition of the invention is useful as a vaccine in the prevention and/or treatment of a tumor disease, particularly melanoma and melanoma residual disease.

Abstract: The present invention relates to a suppressor or inhibitor of the expression and/or the activity of Chitinase 3-like 1 (CHI3L1) for use in the prevention and/or treatment of tumors, wherein said tumors are resistant to antibody-dependent cell-mediated cytotoxicity (ADCC) dependent therapies and/or for use in reducing the risk of developing resistance to antibody-dependent cell-mediated cytotoxicity (ADCC) dependent therapies.

Abstract: Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G?) of at least about 500 Pa.

Abstract: The present invention refers to a composition containing a) a fermented supernatant, or fractions thereof, of Lactobacillus casei or paracasei species, the species being characterized by having in their DNA genome at least one DNA sequence essentially identical to one of the sequence selected from the group consisting of: SEQ ID No 1 to 5, and b) proper carriers and/or diluents and/or excipients. The fermented supernatant is obtainable through a method characterized by the fermentation of the Lactobacillus casei or paracasei species in a minimum solution additioned with prebiotic fibers. The fermented supernatant does not have prebiotic fibers.

Abstract: The present invention refers to a composition including a fermented supernatant of Lactobacillus casei or paracasei species The species is characterized by having in its DNA genome at least one DNA sequence essentially identical to one of the sequences selected from the group consisting of: SEQ ID No 1 to 5, and proper diluents and/or carriers and/or excipients. The compositions can be used in the treatment and/or prevention of skin and/or dermatological diseases related to inflammation, allergic reactions, contact hypersensitivity reactions and intolerance, excessive sebaceous secretion, exfoliation or microbial dysbiosis, preferably of the epidermis.

Abstract: Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G?) of at least about 500 Pa.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G?) of at least about 500 Pa.

Abstract: The invention refers to a composition comprising a fermented product of Lactobacillus casei or paracasei species, preferably for use in the treatment of eye inflammation syndromes and to a method for obtaining the same.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: The present invention refers to a method for obtaining a cell culture supernatant or a fraction thereof having a specific tumor antigen peptide repertoire having the steps of: a) exposing in suitable conditions a tumor cell culture expressing the specific tumor antigen peptide repertoire to a Pattern Recognition Receptor (PRR) agonist and/or to one inflammatory cytokine to increase the opening of connexin-hemichannels (CxH); b) collecting the cell culture supernatant; and c) optionally obtaining a fraction of the supernatant, wherein the supernatant has MHC class I and MHC class II peptides and non-classical MHC molecules (HLA-E).

Abstract: Compositions and methods are provided for treating a gut permeability-related disease or disorder comprising administering to the gastrointestinal tract of a subject in need thereof, a therapeutically effective amount of a hydrogel having an elastic modulus (G?) of at least about 500 Pa.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 are administered to a pregnant or lactating mother in order to treat or attenuate the severity of a microbial infection in her offspring.

Abstract: The present invention relates to a compound selected in the group consisting of: a) a polypeptide consisting of the C-terminus amino acid sequence of the human Thymic stromal lymphopoietin (TSLP) long isoform (SEQ ID NO: 2), derivatives and fragments thereof; b) a polynucleotide coding for said polypeptide; d) a vector comprising said polynucleotide; c) a host cell genetically engineered expressing said polypeptide, or d) a TSLP long isoform (SEQ ID NO:2) antagonist for use in the treatment or/and prevention and/or diagnosis and/or monitoring of a disorder or pathology characterized by an inflammatory response.

Abstract: It is disclosed a method for obtaining a specific tumor antigen peptide repertoire loaded and/or activated dendritic cell comprising the steps of: a) exposing in suitable conditions a tumor cell expressing said specific tumor antigen peptide repertoire to at least one Pattern Recognition Receptor (PRR) agonist and/or to an inflammatory cytokine to obtain a tumor cell with an increased activity of at least one protein belonging to the group of connexins; b) co-culturing said tumor cell with an increased activity of at least one protein belonging to the group of connexins with dendritic cells, to get specific tumor antigen peptide repertoire loaded and/or activated dendritic cells; Step a) and b) are performed simultaneously or in sequence. The group of connexins preferably consists of connexin 43, connexin 40, connexin 45, connexin 47, connexin 50.

Abstract: The involvement of intestinal microbiota in the initiation and perpetuation of inflammatory bowel disease is widely accepted. To reestablish the homeostasis of the gut the use of probiotics has been proposed, with however, limited clinical benefit. This invention relates to an assay based on the modulation of the immunological activity in DCs (dendritic cells) by probiotic strains, in particular L. paracasei and their use in protecting against inflammatory bowel and liver diseases.